Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 5.2% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (NYSE: EW) is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. The company is known for its transcatheter heart valves and hemodynamic monitoring technologies.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 5.2% on Jul 25, 2025 19:55

• Edwards Lifesciences (EW) experienced a strong bullish movement today following its Q2 earnings report.
• The company reported Q2 sales of $1.53 billion, surpassing the estimated $1.49 billion, and an EPS of $0.67, higher than the expected $0.62.
• The positive results were primarily driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments.
• Analysts have increased their forecasts for EW after the robust Q2 results, with a price target also being raised to $101 on the company's growth momentum. The raised FY25 sales outlook further contributed to the bullish sentiment surrounding the stock.

EW Price Chart

EW Technical Analysis

EW News

Edwards Lifesciences Q2 Earnings - Edwards Lifesciences ( NYSE:EW )

Q2 sales hit $1.53 billion vs. $1.49 billion est., EPS at $0.67 vs. $0.62 est.; TAVR up 8.9%, TMTT up 61.9%. FY25 sales outlook raised to $5.90 billion-$6.10 billion; Goldman lifts price target to $101 on growth momentum. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46639989/edwards-lifesciences-lifts-2025-outlook-on-strong-first-half-performance

Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Edwards Lifesciences ( NYSE:EW )

Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday. Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus ...

https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46631056/edwards-lifesciences-analysts-increase-their-forecasts-after-stronger-than-exp

Curious about Edwards Lifesciences ( EW ) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

https://www.zacks.com/stock/news/2599417/curious-about-edwards-lifesciences-ew-q2-performance-explore-wall-street-estimates-for-key-metrics

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.0% Today

XRP ($XRP) Crypto Forecast: Up 5.2% Today

Solana ($SOL) Crypto Forecast: Up 5.1% Today

Toncoin ($TON) Crypto Forecast: Up 5.6% Today

Aave ($AAVE) Crypto Forecast: Up 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.4% Today

VeChain ($VET) Crypto Forecast: Up 5.2% Today

Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 5.2% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 6.6% Today

Intel Corporation ($INTC) Stock Forecast: Down 9.6% Today

Edwards Lifesciences Corporation Price History

18.10.2024 - EW Stock was up 3.6%

• Despite facing multiple securities class action lawsuits and allegations of securities law violations, Edwards Lifesciences (EW) saw a strong bullish movement in the market today.
• Investors might be optimistic about the company's ability to navigate through the legal challenges and maintain its market position.
• The bullish trend could also be attributed to positive developments in the company's core business operations or potential market opportunities that investors are anticipating.
• It appears that market sentiment towards Edwards Lifesciences (EW) remains resilient in the face of legal uncertainties, driving the stock price higher.

30.09.2024 - EW Stock was down 4.7%

• Lawsuits and alerts about losses appear to have impacted investor confidence in Edwards Lifesciences Corporation (EW).
• Trading trends show a significant focus on put options, suggesting a bearish sentiment among investors.
• An upcoming deadline for investors who purchased shares during a specific period may have contributed to the selling pressure on EW stock.
• Overall, negative news flow and legal actions surrounding EW likely influenced the bearish market movement observed today.

24.03.2025 - EW Stock was up 7.2%

• Strong bullish movement in the stock today.
• Analysts upgraded the stock as the growth outlook brightened, with Q1 sales rising 58% YoY and beating consensus estimates.
• Q1 earnings and revenues surpassed expectations, leading to a raised sales view for 2025.
• The market responded positively to the company's performance and optimistic outlook, driving the stock price higher.

24.03.2025 - EW Stock was up 5.0%

• Q1 earnings and revenues of Edwards Lifesciences (EW) surpassed expectations, resulting in a surge in the stock price.
• The company's unique portfolio of therapies likely played a role in its strong market performance.
• An increased sales outlook for 2025 reflects positive market sentiment and confidence in the company's future growth.
• Analysts are delving into various key metrics beyond standard estimates, indicating a profound understanding of Edwards Lifesciences' potential for sustained success.

04.11.2024 - EW Stock was up 5.1%

• Today, the positive outlook outlined at an investor conference contributed to the bullish movement in Edwards Lifesciences' stock. The company is anticipated to experience growth in total sales and therapy segments.
• Despite dealing with investor class action lawsuits and alerts from various law firms, the market appears to be more interested in the company's growth potential and financial prospects.
• Investors are showing optimism towards the potential expansion in TAVR and TMTT sales, potentially overshadowing the legal hurdles currently faced by the company.
• The recent market trend indicates that investors are primarily influenced by Edwards Lifesciences' future growth opportunities rather than its ongoing legal challenges, resulting in an upward momentum in the stock price.

04.11.2024 - EW Stock was up 5.6%

• The bullish movement in EW stock could be attributed to investors gaining confidence in the company's ability to navigate through the legal challenges it is currently facing.
• Despite the negative news surrounding class action lawsuits and investor losses, the stock's bullish movement suggests that investors may believe the company will successfully address these issues and continue to thrive in its industry.
• The upcoming deadlines for filing lawsuits may have created a sense of urgency among investors, leading to increased trading activity and a surge in the stock price.
• It is essential for investors to closely monitor any developments related to the legal proceedings and assess the potential impact on the company's financial performance in the future.

25.06.2025 - EW Stock was up 3.9%

• Edwards Lifesciences (EW) saw a significant uptrend in the market today.
• This rise is linked to the company outperforming expectations in their second-quarter financial results, exceeding projected earnings.
• Additionally, analysts raised their forecasts for EW following the strong Q2 results, further boosting investor confidence.
• The positive market response to the company's strong performance and positive outlook led to an increase in the stock price.

25.06.2025 - EW Stock was up 6.6%

• Q2 results for Edwards Lifesciences (EW) are believed to have surpassed expectations from analysts.
• The company's strong performance in key metrics may have boosted investor confidence, influencing the bullish movement.
• The robust Q2 performance could signal innovation and market responsiveness, attracting more investors and potentially increasing the stock price.

25.06.2025 - EW Stock was up 5.2%

• Edwards Lifesciences (EW) experienced a strong bullish movement today following its Q2 earnings report.
• The company reported Q2 sales of $1.53 billion, surpassing the estimated $1.49 billion, and an EPS of $0.67, higher than the expected $0.62.
• The positive results were primarily driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments.
• Analysts have increased their forecasts for EW after the robust Q2 results, with a price target also being raised to $101 on the company's growth momentum. The raised FY25 sales outlook further contributed to the bullish sentiment surrounding the stock.

28.00.2025 - EW Stock was up 3.6%

• Smart money is showing a bullish sentiment by betting big on Edwards Lifesciences options, indicating confidence in the company's future performance.
• This significant bullish activity from high-rolling investors could be driven by positive developments within the company, such as promising clinical trial results or new product launches.
• Retail traders should pay attention to this trend as it suggests a potential upward momentum in EW's stock price in the near future.
• Overall, the strong bullish movement in EW today may be attributed to the optimistic outlook and strategic positioning of institutional investors in the company.

28.00.2025 - EW Stock was up 5.0%

• Analysts predict a decrease in earnings for Edwards Lifesciences, but significant investment in the company's options indicates a positive market sentiment.
• The discrepancy between analyst forecasts and market behavior suggests investor anticipation of future growth or positive company developments.
• The rise in EW's stock price may be linked to the confidence displayed by high-stakes investors in the company's future potential, leading to increased purchasing activity and driving up the stock value.
• Investor interest in Edwards Lifesciences appears driven by a focus on long-term growth prospects and the company's market positioning, rather than short-term earnings forecasts.

12.01.2025 - EW Stock was up 6.6%

• The company reported strong Q4 sales growth, surpassing consensus estimates and showing a 9% increase year-over-year.
• TMTT sales surged by 77% in 2023, driven by the adoption of PASCAL and EVOQUE, significantly contributing to the positive overall performance.
• TAVR sales performed robustly, reaching $1.04B in Q4 with a 5.3% increase year-over-year, additionally boosting the stock's positive movement.
• Analysts remain confident in Edwards Lifesciences' long-term prospects, which is evident in the positive market sentiment and today's bullish stock movement.